(UroToday.com) In EV-301, a randomized, open-label phase 3 study, enfortumab vedotin, a Nectin-4–directed therapy, significantly prolonged median overall survival by ̃3.9 months and reduced the risk of death by 30% compared with standard chemotherapy (docetaxel, paclitaxel, or vinflunine) in patients with previously treated locally advanced/metastatic urothelial carcinoma.1 Characterizing patient-reported outcomes using a systematic process with a validated instrument provides evidence to support informed decision-making by patients, physicians, policy makers, and payers. Furthermore, understanding patient perspectives and experiences is important to further contextualize the benefits/risks of enfortumab vedotin. At the 2021 American Society of Clinical Oncology (ASCO) virtual annual meeting, Dr. Ronac Mamtani reported results of key prespecified quality-of-life endpoints, a secondary objective of EV-301.